Skip to search formSkip to main contentSkip to account menu

BB-10901

An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide… 
National Institutes of Health

Related topics

Related topics

1 relation
huN901-DM1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Novel Therapies for the Treatment of Small-Cell Lung Cancer
Small-cell lung cancer accounts for up to one-fifth of all lung cancers diagnosed. While the response rates to chemotherapy are… 
2008
2008
510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours
2007
2007
Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.
Background: huN901-DM1 (BB-10901) is a humanized monoclonal antibody that binds with high affinity to CD56 and is covalently… 
2006
2006
Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.
Background: BB-10901 is a humanized monoclonal antibody that binds with high affinity to CD56 and is covalently linked to a novel… 
2006
2006
649 POSTER Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors
2003
2003
In vitro and in vivo antitumor activity of the maytansinoid immunoconjugate BB-10901 (huN901-DM1) on CD56+multiple myeloma cells.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)